In Brief: Nicorette exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Nicorette exclusivity: Washington, D.C. law firm McKenna & Cuneo petitions FDA on Feb. 16 for stay of action regarding the issuance of three-year market exclusivity for SmithKline Beecham's recently approved smoking cessation gum until the agency responds to a Nov. 2 citizen petition from the same firm. The earlier petition, filed on behalf of an unnamed "pharmaceutical" client, argues that Nicorette should not be granted exclusivity because it does not represent a "significant innovation" and the switch is not based on clinical trials ("The Tan Sheet" Nov. 20, 1995, p.2)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning